

1648



U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

**SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT**

Docket Number:
11245/46211

Application Number
10/091,300

Filing Date
March 4, 2002

Examiner
**Art Unit
1648**

Invention Title

**COMBINATION METHODS OF INHIBITING TUMOR
GROWTH WITH A VASCULAR ENDOTHELIAL
GROWTH FACTOR RECEPTOR ANTAGONIST**


Inventor(s)
ROCKWELL et al.

Address to:

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with the
United States Postal Service with sufficient postage as first class mail in an envelope
addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313
1450 on

Date: February 6, 2004

By: 
Kathryn M. Lumb (Reg. No. 46,885)

RECEIVED
FEB 12 2004
TECH CENTER 1600/2900


1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 37 C.F.R. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicants hereby bring the attached references to the attention of the Examiner. These references are listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.
2. The filing of this Information Disclosure Statement and the attached PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b).
3. A copy of each patent, publication or other information listed on the modified PTO form 1449 is enclosed.
4. It is believed that no fees are due in connection with this Information Disclosure Statement. However, should any fees be due, the Commissioner is authorized to charge or credit any over payment to Deposit Account No. ~~101-1010~~. A duplicate copy of this communication is enclosed for charging purposes.

Dated: February 6, 2004

By:


Kathryn M. Lumb (Reg. No. 46,885)

KENYON & KENYON
One Broadway
New York, N.Y. 10004
(212) 425-7200 (Telephone)
(212) 425-5288 (Facsimile)
CUSTOMER NO. 26646



U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

**SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT**


Application Number 10/091,300	Filing Date March 4, 2002	Examiner	Art Unit 1648
Invention Title COMBINATION METHODS OF INHIBITING TUMOR GROWTH WITH A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR ANTAGONIST		Inventor(s) ROCKWELL et al.	

Address to:

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

Date: February 6, 2004


By: 
Kathryn M. Lumb (Reg. No. 46,885)

RECEIVED
FEB 12 2004
TECH CENTER 1600/2900


1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 37 C.F.R. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicants hereby bring the attached references to the attention of the Examiner. These references are listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.
2. The filing of this Information Disclosure Statement and the attached PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b).
3. A copy of each patent, publication or other information listed on the modified PTO form 1449 is enclosed.
4. It is believed that no fees are due in connection with this Information Disclosure Statement. However, should any fees be due, the Commissioner is authorized to charge or credit any over payment to Deposit Account No. 11-0600. A duplicate copy of this communication is enclosed for charging purposes.

Dated: February 6, 2004

By:


Kathryn M. Lumb (Reg. No. 46,885)

KENYON & KENYON
One Broadway
New York, N.Y. 10004
(212) 425-7200 (Telephone)
(212) 425-5288 (Facsimile)
CUSTOMER NO. 26646



SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT PTO-1449		ATTY. DOCKET NO. 11245/46211	SERIAL NO. 10/091,300
		APPLICANT ROCKWELL, et al.	
		FILING DATE March 4, 2002	GROUP 1648

U. S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE*
	6,342,219	January 29, 2002	Thorpe et al.			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES NO

OTHER DOCUMENTS

EXAMINER INITIAL	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
	Johnson D.L. et al., Dual inhibitors of the BFGF and VEGF receptor tyrosine kinases effectively inhibit angiogenesis. Proceedings of the American Associate for Cancer Research March 2000. Vol 41, Page 567. Abstract 3614
	Hooper H.A. et al., Vascular endothelial growth factor receptor (VEGFR-2) antibody therapy combined with conventional chemotherapy inhibits growth of established tumors in mice. Proceedings of the American associate for Cancer Research. March 2000 Vol. 41 page 567. Abstract 3613
	Mordenti J. et al., Efficacy and Concentration-response to murine anti-VEGF monoclonal antibody in tumor-bearing mice and extrapolation to humans. Toxicologic Pathology 1999. Vol. 27, No. 1 pp. 14-21
	Hirota N. et al. Suppression of an epidermal growth factor receptor-hyperproducing tumor by an immunotoxin conjugate of gelonin and monoclonal anti-epidermal growth factor receptor antibody. Cancer Research 1989, Vol. 49

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	